Should oncologists be aware in their clinical practice of KRAS molecular analysis?
Daniele
D
Santini
Sara
S
Galluzzo
Laura
L
Gaeta
Alice
A
Zoccoli
Elisabetta
E
Riva
Annamaria
A
Ruzzo
Bruno
B
Vincenzi
Francesco
F
Graziano
Fotios
F
Loupakis
Alfredo
A
Falcone
Andrea Onetti
AO
Muda
Giuseppe
G
Tonini
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001291:Attitude of Health Personnel; D001364:Awareness; D003062:Codon; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000556:secondary; D004252:DNA Mutational Analysis; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D005820:Genetic Testing / Q000379:methods*; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D058990:Molecular Targeted Therapy; D009154:Mutation; D018579:Patient Selection; D016133:Polymerase Chain Reaction; D057285:Precision Medicine; D011237:Predictive Value of Tests; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D016283:Proto-Oncogene Proteins p21(ras); D012189:Retrospective Studies; D018631:ras Proteins / Q000235:genetics*
D000970:Antineoplastic Agents; D003062:Codon; C117307:KRAS protein, human; D047428:Protein Kinase Inhibitors; D011518:Proto-Oncogene Proteins; C512478:EGFR protein, human; D066246:ErbB Receptors; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins